Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Martin Maron

Cardiovascular Disease Burlington, MA Medical Doctor

NPI 1225146905 CMS profile 1081384

41 Mall Rd, Burlington, MA 01805

Open in the dashboard

General payments

$89,786

52 records reported · program years 2019–2025

Research payments

$4,895

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,787,836 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Martin Maron of Burlington, MA is reported in the CMS Open Payments database as having received $89,786 across 52 general payments and $4,895 in research payments paid to them. Separately, studies naming them as principal investigator received $3,787,836 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,539 9
2025 Research $4,895 1
2024 General $1,519 5
2023 General $15,705 17
2022 General $8,191 4
2021 General $27,600 6
2020 General $16,737 7
2019 General $5,495 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Martin Maron
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Martin Maron were reported at $14,539. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Martin Maron Cardiovascular Disease median Middle half National median
2019 $5,495 $450 $127–$1,392 $163
2020 $16,737 $242 $77–$751 $114
2021 $27,600 $335 $101–$1,037 $132
2022 $8,191 $395 $121–$1,211 $149
2023 $15,705 $443 $136–$1,283 $160
2024 $1,519 $450 $136–$1,323 $164
2025 $14,539 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Takeda Pharmaceutical Company, Limited $17,471 5 payments
  2. Genzyme Corporation $17,060 5 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $13,800 3 payments
  4. iRhythm Technologies, Inc. $11,764 15 payments
  5. Amicus Therapeutics, Inc. $9,004 2 payments
  6. Pfizer Inc. $5,075 5 payments
  7. Celltrion, Inc. $5,000 1 payment
  8. Alexion Pharmaceuticals, Inc. $3,902 3 payments
  9. Novo Nordisk AS $3,140 2 payments
  10. Medtronic Vascular, Inc. $2,100 1 payment
  11. Other $1,469 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $75,563 25 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,086 6 payments
  3. Travel and Lodging $1,926 5 payments
  4. Education $1,175 1 payment
  5. Food and Beverage $1,036 15 payments
Products named General payments · program years 2019–2025
  1. ZIO XT Patch $11,764 15 payments
  2. GALAFOLD $9,004 2 payments
  3. FABRAZYME $5,230 2 payments
  4. CAMZYOS $142 3 payments
  5. RESONATE EL ICD VR $129 1 payment
  6. Zio monitor $117 1 payment
  7. JARDIANCE $52 2 payments
  8. PRADAXA $52 2 payments
  9. LifeVest $30 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $4,895 1 payment

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$33,049

Medicare's payments for the services billed

Medicare patients

440

Average age 73

Services billed

838

224 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 44%
Arthritis 43%
Ischemic heart disease 40%
Heart failure 37%
Diabetes 28%
Chronic kidney disease 26%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record